Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gaurav Jain

Internal Medicine Williamsville, NY Medical Doctor

NPI 1447416979 CMS profile 292111

400 International Dr., Williamsville, NY 14221

Open in the dashboard

General payments

$7,429

97 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gaurav Jain of Williamsville, NY is reported in the CMS Open Payments database as having received $7,429 across 97 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $439 15
2024 General $219 7
2023 General $401 8
2022 General $3,210 23
2021 General $1,063 12
2020 General $683 10
2019 General $1,413 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gaurav Jain
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gaurav Jain were reported at $439. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gaurav Jain Internal Medicine median Middle half National median
2019 $1,413 $159 $48–$570 $163
2020 $683 $119 $33–$402 $114
2021 $1,063 $135 $37–$521 $132
2022 $3,210 $141 $42–$496 $149
2023 $401 $149 $45–$519 $160
2024 $219 $154 $47–$537 $164
2025 $439 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,807 20 payments
  2. Stryker Corporation $2,656 34 payments
  3. Abbott Laboratories $1,229 20 payments
  4. Vertos Medical, Inc. $151 3 payments
  5. Alphatec Spine, Inc $137 1 payment
  6. Globus Medical, Inc. $131 5 payments
  7. Nevro Corp. $105 4 payments
  8. Vertex Pharmaceuticals Incorporated $46 2 payments
  9. Lundbeck LLC $27 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $27 1 payment
  11. Other $114 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,445 81 payments
  2. Travel and Lodging $2,984 16 payments
Products named General payments · program years 2019–2025
  1. Superion Indirect Decompression System $2,511 14 payments
  2. BIO4 $1,704 22 payments
  3. TRITANIUM Hips $1,513 16 payments
  4. STRYKER NAV3I $1,431 15 payments
  5. Proclaim Family of SCS IPGs $797 9 payments
  6. ES2 SPINAL SYSTEM $720 10 payments
  7. XIA 3 $595 5 payments
  8. ES2 $586 8 payments
  9. TRITANIUM Hips $533 8 payments
  10. NAV -3INAVIGATION PLATFORM $275 3 payments
  11. Other $1,813 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,367

Median for Pain Management: 951

Drug cost

$25,394

Median for Pain Management: $26,034

Branded share of claims

9.9%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 501 $8,407
Pregabalin Generic 114 $4,713
Duloxetine Hcl Generic 195 $3,454
Lidocaine Generic 18 $2,670
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 83 $1,958
Tramadol Hcl Generic 176 $786
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 53 $695
Cyclobenzaprine Hcl Generic 29 $476
Methadone Hcl Generic 25 $392
Topiramate Generic 38 $382

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$239,588

Medicare's payments for the services billed

Medicare patients

708

Average age 72

Services billed

3,099

427 women, 281 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 30%
Diabetes 26%
Ischemic heart disease 25%
COPD 22%
Osteoporosis 22%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record